BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
140 results:

  • 1. AKTing on R Loops Makes for an atractive Target in Ovarian cancer Therapy.
    Ramanarayanan V; Oberdoerffer P
    Cancer Res; 2024 Mar; 84(6):793-795. PubMed ID: 38486481
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
    Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
    J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian cancer.
    Huang TT; Chiang CY; Nair JR; Wilson KM; Cheng K; Lee JM
    Cancer Res; 2024 Mar; 84(6):887-904. PubMed ID: 38241710
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
    Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
    Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeted inhibition of the atr/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
    Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
    Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic cancer.
    Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
    Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian cancer.
    Nasioudis D; George EM; Xu H; Kim H; Simpkins F
    Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mechanisms of PARP Inhibitor Resistance.
    O'Connor MJ; Forment JV
    Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Therapeutic inhibition of atr in differentiated thyroid cancer.
    Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
    Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
    Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. DNA2 Nuclease Inhibition Confers Synthetic Lethality in cancers with Mutant p53 and Synergizes with PARP Inhibitors.
    Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
    Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer.
    Ren L; Qing X; Wei J; Mo H; Liu Y; Zhi Y; Lu W; Zheng M; Zhang W; Chen Y; Zhang Y; Pan T; Zhong Q; Li R; Zhang X; Ruan X; Yu R; Li J
    Cell Death Dis; 2023 Aug; 14(8):568. PubMed ID: 37633920
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
    Altimari M; Wells A; Abad J; Chawla A
    Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
    Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
    Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
    Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
    Commun Biol; 2023 Jun; 6(1):660. PubMed ID: 37349576
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Relationship between circulating tumour DNA and skeletal muscle stores at diagnosis of pancreatic ductal adenocarcinoma: a cross-sectional study.
    Hanna L; Sellahewa R; Huggins CE; Lundy J; Croagh D
    Sci Rep; 2023 Jun; 13(1):9663. PubMed ID: 37316578
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. DNA Repair Pathway in Ovarian cancer Patients Treated with HIPEC.
    Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Fast and label-free intraoperative discrimination of malignant pancreatic tissue by attenuated total reflection infrared spectroscopy.
    Bandzeviciute R; Steiner G; Liedel K; Golde J; Koch E; Welsch T; Kahlert C; Stange DE; Distler M; Weitz J; Ceponkus J; Sablinskas V; Teske C
    J Biomed Opt; 2023 Apr; 28(4):045004. PubMed ID: 37122477
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Combination atr (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian cancer.
    Wethington SL; Shah PD; Martin L; Tanyi JL; Latif N; Morgan M; Torigian DA; Rodriguez D; Smith SA; Dean E; Domchek SM; Drapkin R; Shih IM; Brown EJ; Hwang WT; Armstrong DK; Gaillard S; Giuntoli R; Simpkins F
    Clin Cancer Res; 2023 Aug; 29(15):2800-2807. PubMed ID: 37097611
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.